KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Assets: 2020-2024

Historic Current Assets for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $714.3 million.

  • Recursion Pharmaceuticals' Current Assets rose 50.60% to $714.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $714.1 million, marking a year-over-year increase of 50.60%. This contributed to the annual value of $714.3 million for FY2024, which is 63.02% up from last year.
  • As of FY2024, Recursion Pharmaceuticals' Current Assets stood at $714.3 million, which was up 63.02% from $438.1 million recorded in FY2023.
  • Recursion Pharmaceuticals' Current Assets' 5-year high stood at $714.3 million during FY2024, with a 5-year trough of $266.4 million in FY2020.
  • For the 3-year period, Recursion Pharmaceuticals' Current Assets averaged around $574.1 million, with its median value being $569.8 million (2022).
  • Its Current Assets has fluctuated over the past 5 years, first spiked by 100.69% in 2021, then fell by 23.11% in 2023.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Current Assets stood at $266.4 million in 2020, then soared by 100.69% to $534.7 million in 2021, then climbed by 6.56% to $569.8 million in 2022, then fell by 23.11% to $438.1 million in 2023, then spiked by 63.02% to $714.3 million in 2024.